Two BCBS-affiliated Plans Issue Positive Coverage Policies for Veracyte's Afirma GEC Test | GenomeWeb

NEW YORK (GenomeWeb) – Veracyte said today that Highmark and Horizon Blue Cross Blue Shield of New Jersey issued positive coverage policies for the company's Afirma Gene Expression Classifier.

Both insurers are affiliated with Blue Cross Blue Shield and have classified Veracyte's genomic test as medically necessary for use in evaluating thyroid nodule fine needle aspiration biopsies that are indeterminate following traditional cytopathology review. The Afirma GEC test helps physicians determine which patients may need surgery as part of a thyroid cancer diagnosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.